Compugen to Present at Two Immuno-Oncology Conferences in April
April 06 2015 - 7:10AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug
discovery company, today announced that Anat Cohen-Dayag, PhD,
President and Chief Executive Officer, Compugen, will present
aspects of the Company’s immune checkpoint programs at two oncology
conferences in Boston this month.
Dr. Cohen-Dayag will deliver a presentation at the Jefferies
Immuno-Oncology Summit, to be held on April 15, 2015. In her talk,
Dr. Cohen-Dayag will discuss Compugen’s broadly applicable
predictive discovery approach with emphasis on its first focused
discovery program, which resulted in the identification of multiple
novel immune checkpoint candidates. Dr. Cohen-Dayag will also
present experimental data for selected Compugen-discovered novel
immune checkpoints now being advanced by the Company as target
candidates for cancer immunotherapy.
In addition, Dr. Cohen-Dayag will participate in a panel
discussion titled Focus on Immunotherapy: The Future at the Cancer
Advance Boston conference at Harvard Medical School, Harvard
University on April 14, 2015.
About Compugen’s Programs for Cancer Immunotherapy
Compugen’s cancer immunotherapy programs are based on eleven
novel B7/CD28-like immune checkpoint candidates and four novel
immunomodulators distinct from the B7/CD28-like proteins, all of
which were initially predicted in silico by Compugen.
Immune checkpoints, including inhibitory receptors and ligands, are
immunomodulatory proteins which are crucial for the maintenance of
self-tolerance (the prevention of autoimmunity) and for the
protection of tissues from damage during an immune response. Immune
checkpoints are "hijacked" by tumors to block the ability of the
immune system to destroy the tumor cells. Therapeutic blockade of
immune checkpoints can boost anti-tumor immunity, enabling the
patient’s immune system to recognize and attack the tumor cells,
and mount durable anti-tumor responses leading to tumor
destruction.
About Compugen
Compugen is a leading predictive drug discovery company focused
on monoclonal antibodies and therapeutic proteins to address
important unmet needs in the fields of oncology and
immunology. The Company utilizes a broad and continuously
growing integrated infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine
learning systems and other computational biology capabilities for
the in silico (by computer) prediction and selection of
novel drug target candidates, which are then advanced in its
Pipeline Program. The discovery and development of monoclonal
antibody therapeutic candidates against selected
Compugen-discovered novel target candidates is performed by
Compugen’s wholly-owned U.S. subsidiary located in South San
Francisco. The Company's business model includes collaborations
covering the further development and commercialization of product
candidates at various stages from its Pipeline Program and various
forms of research and discovery agreements, in both cases providing
Compugen with potential milestone payments and royalties on product
sales or other forms of revenue sharing. For additional
information, please visit Compugen's corporate website at
www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as “will,” “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these risks
include: that Compugen’s business model is substantially dependent
on entering into collaboration agreements with third parties and
may not be successful in generating revenues, and that the
development and commercialization of therapeutic products includes
many inherent risks, including failure to receive regulatory
approval. These and other factors are more fully discussed in the
"Risk Factors" section of Compugen’s most recent Annual Report on
Form 20-F as filed with the Securities and Exchange Commission as
well as other documents that may be subsequently filed by Compugen
from time to time with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Compugen’s views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Compugen does
not assume any obligation to update any forward-looking statements
unless required by law.
Compugen Ltd.Tsipi Haitovsky, +972-52-598-9892Global Media
Liaisontsipih@cgen.com
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024